Your browser doesn't support javascript.
loading
Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Ge, Wenzhen; Wu, Ning; Jalbert, Jessica J; Quek, Ruben G W; Liu, Jinjie; Rietschel, Petra; Pouliot, Jean-Francois; Harnett, James; Hsu, Melinda Laine; Feliciano, Josephine L.
  • Ge W; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Wu N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Jalbert JJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Quek RGW; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Liu J; Genesis Research, LLC, Hoboken, NJ, USA.
  • Rietschel P; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Pouliot JF; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Harnett J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Hsu ML; University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
  • Feliciano JL; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cancer Manag Res ; 14: 3191-3202, 2022.
Article en En | MEDLINE | ID: mdl-36415537
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article